Arcutis Biotherapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) develops and commercializes topical therapies for immune-mediated inflammatory skin diseases, including plaque psoriasis, atopic dermatitis, seborrheic dermatitis, scalp and body psoriasis, hidradenitis suppurativa, and vitiligo; its lead product, ZORYVE (roflumilast cream 0.3% and 0.15%), is FDA-approved for plaque psoriasis in adults and children aged 2 years and older, atopic dermatitis in adults and children aged 3 months and older (including low-dose formulations of 0.05% for ages 2-5 years and 3-24 months), and seborrheic dermatitis; ZORYVE foam (roflumilast 0.3%) is FDA-approved for seborrheic dermatitis and scalp and body psoriasis in adults; the company advances a pipeline featuring topical roflumilast across additional indications and ARQ-234, a topical biologic CD200R agonist in Phase 1 for atopic dermatitis. Founded in 2016 and headquartered in Westlake Village, California, Arcutis operates primarily in the United States, with partnerships extending to markets including China via Huadong Medicine, from which it received milestone payments of $3 million in Q1 2024 and $2 million in Q1 2025. Recent developments include robust ZORYVE sales growth to $99.2 million in Q3 2025, up significantly year-over-year, alongside FDA approval expansions for pediatric indications, preparation to initiate a Phase 1 trial for ARQ-234, and awards such as the 2025 Best of Beauty Breakthrough for ZORYVE cream and foam; the company continues strategic pipeline evaluation, including potential external innovations and a partnership with Kowa, while shifting market dynamics away from topical steroids.
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines